C07C255/62

Compounds for the treatment of mTOR pathway related diseases

The present invention relates to compounds for the treatment of mTOR (mammalian Target Of Rapamycin) pathway related diseases. Specifically, the present invention relates to the use of aminoactonitrile derivatives (AADs) in the treatment of mTOR pathway related diseases.

Compounds for the treatment of mTOR pathway related diseases

The present invention relates to compounds for the treatment of mTOR (mammalian Target Of Rapamycin) pathway related diseases. Specifically, the present invention relates to the use of aminoactonitrile derivatives (AADs) in the treatment of mTOR pathway related diseases.

Bicyclic alkyl compounds and synthesis

Disclosed herein are compounds of the general Formula (I), and methods of synthesizing a substituted bicyclo[1.1.1]pentane using a Group VII or Group IX transition metal compound.

Bicyclic alkyl compounds and synthesis

Disclosed herein are compounds of the general Formula (I), and methods of synthesizing a substituted bicyclo[1.1.1]pentane using a Group VII or Group IX transition metal compound.

COMPOUNDS FOR THE TREATMENT OF MTOR PATHWAY RELATED DISEASES

The present invention relates to compounds for the treatment of mTOR (mammalian Target Of Rapamycin) pathway related diseases. Specifically, the present invention relates to the use of aminoacetonitrile derivatives (AADs) in the treatment of mTOR pathway related diseases.

COMPOUNDS FOR THE TREATMENT OF MTOR PATHWAY RELATED DISEASES

The present invention relates to compounds for the treatment of mTOR (mammalian Target Of Rapamycin) pathway related diseases. Specifically, the present invention relates to the use of aminoacetonitrile derivatives (AADs) in the treatment of mTOR pathway related diseases.